Business Context and Reporting Period
ImmuCell Corporation (ICCC) filed a Form 8-K on June 11, 2024, reporting the entry into a material definitive agreement. The filing concerns a Fourth Amendment to a lease agreement for the company's principal executive offices located at 175 Industrial Way, Portland, Maine.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or overall debt levels. It specifically details a restructuring of a specific lease payment obligation:
- Original Obligation: A one-time rent payment of $488,743 previously due in July 2024.
- Revised Payment Structure:
- Monthly payments of $20,000 from July 2024 through December 2024 (Total: $120,000).
- A one-time payment of $368,743 due in January 2025.
- Total Liability: The total amount payable remains $488,743.
Material Changes
The material change involves the timing of cash outflows rather than the total liability amount. The company has deferred a significant portion of the payment originally due in July 2024 to January 2025, replacing a lump-sum payment with a combination of monthly installments and a deferred lump sum.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general risks. The primary contingency noted is the company's obligation to adhere to the new payment schedule for tenant improvements on the leased premises.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can meet the monthly $20,000 payments starting July 2024.
- Confirm the total outstanding lease obligations in the company's most recent 10-Q or 10-K to assess the impact of the January 2025 payment.
- Review the full text of Exhibit 10.1 (Fourth Amendment of Lease) for any additional covenants or conditions not summarized in the 8-K.